15 days ago
The stock market has its dips, but historically, Apple (APPL) stock has done well for investors. As of Oct. 1, it traded for $330.32 — a nearly 30% yearly increase, according to Yahoo Finance. Take it back further to 2016, and the stock has gone up by a little over 1,063%.
As a new investor, you might be thinking Apple stock is the perfect buy. However, as with any other investment, it's not without risk. These are some of the most common mistakes investors make when buying stocks, according to financial advisors Ed Peagler and Xintian **** .
As per J.P. Morgan, the general advice when it comes to stocks is to put no more than 10% to 20% of your total portfolio in one stock. Of course, when you see the numbers rising on a particular stock, it's easy to get excited and make investment choices based on that.
This can be a mistake, though.
"Apple is a spectacular company that most people already know and love. It's no surprise, then, that many individuals end up with too large a position in their overall portfolio. And they don't feel like they have a high concentration stock because it's Apple. They trust it," said Xintian **** , CPA, senior tax manager at Alexander Accountants, CPAs. "But high concentration is high concentration. And it amplifies the risk of an unsafe, underestimated stock."
#concentration #according
As a new investor, you might be thinking Apple stock is the perfect buy. However, as with any other investment, it's not without risk. These are some of the most common mistakes investors make when buying stocks, according to financial advisors Ed Peagler and Xintian **** .
As per J.P. Morgan, the general advice when it comes to stocks is to put no more than 10% to 20% of your total portfolio in one stock. Of course, when you see the numbers rising on a particular stock, it's easy to get excited and make investment choices based on that.
This can be a mistake, though.
"Apple is a spectacular company that most people already know and love. It's no surprise, then, that many individuals end up with too large a position in their overall portfolio. And they don't feel like they have a high concentration stock because it's Apple. They trust it," said Xintian **** , CPA, senior tax manager at Alexander Accountants, CPAs. "But high concentration is high concentration. And it amplifies the risk of an unsafe, underestimated stock."
#concentration #according
1 month ago
Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
Getting denied for a credit card can be frustrating, but it doesn't necessarily mean you can't qualify for another card. Your first step should be figuring out why your application was rejected.
Credit card issuers can deny applications for many reasons, including your credit history, high balances, recent credit applications, income, or issuer-specific eligibility requirements. After a denial, review the reason the issuer provides before deciding what to do next.
If your credit card application is denied, the issuer must send you an adverse action notice explaining the reasons for the denial or how to request them.
Common reasons for credit card denials include credit history, high credit utilization, too many recent applications, insufficient income, and issuer-specific restrictions.
#issuer #reasons #many #high
Getting denied for a credit card can be frustrating, but it doesn't necessarily mean you can't qualify for another card. Your first step should be figuring out why your application was rejected.
Credit card issuers can deny applications for many reasons, including your credit history, high balances, recent credit applications, income, or issuer-specific eligibility requirements. After a denial, review the reason the issuer provides before deciding what to do next.
If your credit card application is denied, the issuer must send you an adverse action notice explaining the reasons for the denial or how to request them.
Common reasons for credit card denials include credit history, high credit utilization, too many recent applications, insufficient income, and issuer-specific restrictions.
#issuer #reasons #many #high
1 month ago
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise.
On September 3, Citigroup **** yst Geoff Meacham highlighted the strategic importance of the Crinetics acquisition, arguing it could diversify Vertex's business while complementing its existing cystic fibrosis franchise and newer businesses in renal disease, hematology, and pain.
Through the transaction, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) gains access to Palsonify (paltusotine), an oral treatment for acromegaly that has already received regulatory approval in Europe. Paltusotine is also in Phase 3 development for carcinoid syndrome **** ociated with neuroendocrine tumors.
Palsonify is particularly important because it provides an immediate commercial revenue opportunity, rather than requiring the company to wait several years for an entirely new drug to reach the market.
Early uptake of Palsonify has been encouraging, supported by expanding physician adoption and improving reimbursement coverage. If that momentum continues, the drug could become an important contributor to Vertex's revenue growth.
#palsonify
On September 3, Citigroup **** yst Geoff Meacham highlighted the strategic importance of the Crinetics acquisition, arguing it could diversify Vertex's business while complementing its existing cystic fibrosis franchise and newer businesses in renal disease, hematology, and pain.
Through the transaction, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) gains access to Palsonify (paltusotine), an oral treatment for acromegaly that has already received regulatory approval in Europe. Paltusotine is also in Phase 3 development for carcinoid syndrome **** ociated with neuroendocrine tumors.
Palsonify is particularly important because it provides an immediate commercial revenue opportunity, rather than requiring the company to wait several years for an entirely new drug to reach the market.
Early uptake of Palsonify has been encouraging, supported by expanding physician adoption and improving reimbursement coverage. If that momentum continues, the drug could become an important contributor to Vertex's revenue growth.
#palsonify
1 month ago
This week's ETF Zoo crew takes a lay of the land as summer comes to a close and some new and interesting developments crop up. ETF.com hosts Dave Nadig, President & Director of Research, and Sumit Roy, Senior ETF ****** yst, are joined in this episode by Cinthia Murphy, Director of Research at TMX VettaFi, and James Seyffart, CFA, CAIA, Senior Research ****** yst at Bloomberg Intelligence. Together the group talks about some of the big M&A announcements lately, dig into the AI chokepoint perspective, and more.
You can view this episode here or on our YouTube channel or listen on Spotify or Apple Podcasts.
M&A land grab in full swing. Billions in ETF acquisitions, including Victory Capital/First Eagle, Vanguard/Altruist, and more, signal that scale instead of organic growth now drives the industry. The Zoo crew debated whether firms are buying hit products, talent, or distribution, and what could be ahead for the industry.
Leverage and gambling push into new territory. Defiance's hourly-reset leveraged ETFs barely differ from daily resets despite pulling in huge fees, while Korea and ****** an crack down on single-stock leverage entirely. New NHL-linked sports-betting ETFs raised bigger concerns about routing gambling risk through the same rails as retirement savings.
AI concentration is everywhere, even where you don't expect it. Thematic and datacenter ETFs quietly hold the same chokepoint stocks like Micron and Nvidia, sparking debate over whether that's a feature or a vulnerability. However, real revenue growth at companies like Anthropic and OpenAI kept the Zoo Crew from sounding the alarm just yet.
#land #chokepoint
You can view this episode here or on our YouTube channel or listen on Spotify or Apple Podcasts.
M&A land grab in full swing. Billions in ETF acquisitions, including Victory Capital/First Eagle, Vanguard/Altruist, and more, signal that scale instead of organic growth now drives the industry. The Zoo crew debated whether firms are buying hit products, talent, or distribution, and what could be ahead for the industry.
Leverage and gambling push into new territory. Defiance's hourly-reset leveraged ETFs barely differ from daily resets despite pulling in huge fees, while Korea and ****** an crack down on single-stock leverage entirely. New NHL-linked sports-betting ETFs raised bigger concerns about routing gambling risk through the same rails as retirement savings.
AI concentration is everywhere, even where you don't expect it. Thematic and datacenter ETFs quietly hold the same chokepoint stocks like Micron and Nvidia, sparking debate over whether that's a feature or a vulnerability. However, real revenue growth at companies like Anthropic and OpenAI kept the Zoo Crew from sounding the alarm just yet.
#land #chokepoint
